• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
SUBSCRIBE
2 Minute Medicine
Subscribe
EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine
Home All Specialties Cardiology

Detection of pathogenic genetic variants in early-onset atrial fibrillation

byYuchen DaiandMichael Pratte
September 16, 2021
in Cardiology, Chronic Disease, Emergency, Genetics
Reading Time: 3 mins read
Rivaroxaban likely reduces risk of recurrent stroke in specific subgroup of patients with embolic stroke of undetermined source
Share on FacebookShare on Twitter

1. Genetic testing in patients with early-onset atrial fibrillation, via major commercial arrhythmia and cardiomyopathy gene panels, were able to detect a disease-associated variant in approximately 10% of patients, with a higher rate in those diagnosed before the age of 30 years.

2. Disease-associated variants in atrial fibrillation were more common in genes associated with inherited cardiomyopathies than inherited channelopathies.

Evidence Rating Level: 2 (Good)

Study Rundown: Atrial fibrillation (AF) is the most common type of supraventricular tachyarrhythmia where the mainstay of diagnosis and monitoring focuses on the assessment of cardiac rhythm, structure, and function. Currently, genetic testing is not recommended in patients with AF. However, recent data has suggested that early-onset AF may be suggestive of a more serious underlying inherited cardiomyopathy or arrhythmia syndrome. This cohort study analyzed genes currently included on major commercial arrhythmia and cardiomyopathy gene panels to evaluate the frequency of disease-associated variants according to age, specific inherited syndromes, and individual genes. The main endpoint of the analysis was classification of rare variants using American College of Medical Genetics and Genomics (ACMG) criteria: benign, likely benign, variant of undetermined significance, likely pathogenic, or pathogenic. Among 1,293 patients with early-onset AF who underwent whole genome sequencing, disease-associated variants in cardiomyopathy and arrhythmia genes were identified in 10.1% of patients younger than 66 years and 16.8% of individuals younger than 30 years. Furthermore, disease-associated variants were more prevalent in genes associated with inherited cardiomyopathy syndromes than inherited arrhythmia syndromes. These findings suggested that genetic testing in patients with early-onset AF via major commercial arrhythmia and cardiomyopathy gene panels were able to detect a disease-associated variant in approximately 10% of patients, with a higher rate in those diagnosed before the age of 30 years. These results are encouraging in supporting the use of genetic testing in patients presenting with early-onset AF. A limitation of this study was that the patient cohort was consisted predominately of people of European descent where the prevalence of rare variants associated with AF in individuals of underrepresented ethnicities is unclear. Further study is needed on these other ethnic groups to help stratify risk associated with ethnicity and increase generalizability of the study’s findings.

Click to read the study in JAMA Cardiology

Click to read an accompanying editorial in JAMA Cardiology

RELATED REPORTS

Apixaban (Eliquis) is associated with reduced rates of ischemic stroke and bleeding in patients with atrial fibrillation and advanced chronic kidney disease compared with warfarin (Coumadin)

2 Minute Medicine Rewind September 7, 2026

2 Minute Medicine Rewind August 31, 2026

Relevant Reading: Broad genetic testing in a clinical setting uncovers a high prevalence of titin loss-of-function variants in very early onset atrial fibrillation

In-Depth [prospective cohort]: This prospective, single-center, observational cohort study included 1,293 patients with AF (934 [72.2%] male; median [IQR] age at enrollment, 56 [48-61] years; median [IQR] age at AF diagnosis, 50 [41-56] years) diagnosed before 66 years of age from November 1999 to June 2015 and underwent whole genome sequencing through the National Heart, Lung, and Blood Institute’s Trans-Omics for Precision Medicine program. Data analysis was performed between October 2020 and March 2021 where sequencing data from commercial cardiomyopathy and arrhythmia panels (145-gene panel) were analyzed using an automated process followed by manual review by a panel of independent, blinded reviewers. In total, genetic testing identified 131 patients (10.1%) with a disease-associated variant, 812 (62.8%) with a variant of undetermined significance, 92 (7.1%) as heterozygous carriers for an autosomal recessive disorder, and 258 (20.0%) with no suspicious variant. Disease-associated variants were most prevalent in patients diagnosed before the age of 30 years (20 of 119 [16.8%; 95%CI, 10.0%-23.6%]) and lowest after the age of 60 years (8 of 112 [7.1%; 95%CI, 2.4%-11.9%]). Lastly, disease-associated variants were most common in genes associated with inherited cardiomyopathy syndromes than inherited arrhythmia syndromes, where the most affected genes were TTN (n = 38), MYH7 (n = 18), MYH6 (n = 10), LMNA (n = 9), and KCNQ1 (n = 8).

Image: PD

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: atrial fibrillationgenetic mutationgenetic variantrisk stratification
Previous Post

#VisualAbstract: Post-induction chemotherapy Epstein-Barr virus DNA is an effective prognostic indicator for nasopharyngeal carcinomas

Next Post

#VisualAbstract Pembrolizumab after CD19-directed CAR T-cell therapy appears safe and may achieve clinical responses in patients with relapsed/refractory B-cell lymphomas

RelatedReports

Nephrology

Apixaban (Eliquis) is associated with reduced rates of ischemic stroke and bleeding in patients with atrial fibrillation and advanced chronic kidney disease compared with warfarin (Coumadin)

September 9, 2026
Long-term outcomes for off-pump and on-pump CABG are similar
Weekly Rewinds

2 Minute Medicine Rewind September 7, 2026

September 7, 2026
Rivaroxaban likely reduces risk of recurrent stroke in specific subgroup of patients with embolic stroke of undetermined source
Weekly Rewinds

2 Minute Medicine Rewind August 31, 2026

August 31, 2026
Rivaroxaban likely reduces risk of recurrent stroke in specific subgroup of patients with embolic stroke of undetermined source
Cardiology

Catheter ablation within 1 year of atrial fibrillation diagnosis is associated with reduced risk of recurrence

July 24, 2026
Next Post
#VisualAbstract Pembrolizumab after CD19-directed CAR T-cell therapy appears safe and may achieve clinical responses in patients with relapsed/refractory B-cell lymphomas

#VisualAbstract Pembrolizumab after CD19-directed CAR T-cell therapy appears safe and may achieve clinical responses in patients with relapsed/refractory B-cell lymphomas

Hybrid minimally invasive esophagectomy associated with lower complication rates compared to open esophagectomy

Camrelizumab with chemotherapy demonstrated improved overall survival and progression-free survival of esophageal squamous cell carcinoma patients versus placebo

Sleep duration, sleepiness, chronotype have variable associations with teen self-regulation

Mental health in young adults may be linked to sleep chronotype

EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

5-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 5-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Transanastomotic tubes not linked to anastomotic stricture after esophageal atresia repair
  • Artificial intelligence (AI) chatbot reduced depression, anxiety, and eating disorder risk symptoms
  • Real-time AI guidance enters live brain tumor surgery
License Content
Terms of Use | Disclaimer
Cookie Policy
Cleantalk Pixel
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

5-day free trial · cancel anytime

Start 5-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free · only $4.16/month

Start 5-day free trial

Then $49.90/year. Manage renewal in your account.

Membership benefits

  • ✓100+ physician-written reports
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters

Already a member? Sign in

  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.